Review



cd3 receptor  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd3 receptor
    Cd3 Receptor, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+receptor/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/us12611427-401-29-54
    Average 99 stars, based on 47 article reviews
    cd3 receptor - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Variant Assay:

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Expansion of TILs utilizing AKT pathways inhibitors
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Treatment of NSCLC patients refractory for anti-PD-1 antibody
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Magnetic Cell Separation:

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Expansion of TILs utilizing AKT pathways inhibitors
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Treatment of NSCLC patients refractory for anti-PD-1 antibody
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Bioprocessing:

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Expansion of TILs utilizing AKT pathways inhibitors
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Treatment of NSCLC patients refractory for anti-PD-1 antibody
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..

    Article Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
    Article Snippet: .. The term “OKT-3” (also referred to herein as “OKT3”) refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially-available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof. ..



    Similar Products

    cd3 receptor  (Miltenyi Biotec)
    99
    Miltenyi Biotec cd3 receptor
    Cd3 Receptor, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+receptor/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/us12611427-401-29-54
    Average 99 stars, based on 1 article reviews
    cd3 receptor - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    anti mouse cd3 mab  (Bio X Cell)
    98
    Bio X Cell anti mouse cd3 mab
    ( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse <t>CD3</t> antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.
    Anti Mouse Cd3 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+receptor/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pmc12646666-167-19-24
    Average 98 stars, based on 1 article reviews
    anti mouse cd3 mab - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    mouse anti cd3  (Bio X Cell)
    98
    Bio X Cell mouse anti cd3
    ( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse <t>CD3</t> antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.
    Mouse Anti Cd3, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+receptor/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pm40753778-89-15-17
    Average 98 stars, based on 1 article reviews
    mouse anti cd3 - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    anti mouse cd3  (Bio X Cell)
    98
    Bio X Cell anti mouse cd3
    a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + <t>CD3</t> + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.
    Anti Mouse Cd3, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+receptor/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pmc12398490-297-31-36
    Average 98 stars, based on 1 article reviews
    anti mouse cd3 - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse CD3 antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.

    Journal: The Journal of Clinical Investigation

    Article Title: Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes

    doi: 10.1172/JCI176403

    Figure Lengend Snippet: ( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse CD3 antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.

    Article Snippet: RO NOD mice were bled via the submandibular vein and treated for 5 consecutive days with 2.5 μg/d hamster anti–mouse CD3 mAb (clone 145-2C11, BioXCell) and monitored for a period of 28 days (CITE-Seq and follow-up) ( ).

    Techniques: Control, Comparison

    a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + CD3 + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA

    doi: 10.1038/s41467-025-63415-0

    Figure Lengend Snippet: a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + CD3 + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.

    Article Snippet: The isolated CD8 T cells were resuspended in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin, and 0.1% 2-mercaptoethanol (Thermo Fisher Scientific) and then cultured in a 48-well plate pretreated with anti-mouse CD3 and CD28 antibodies (Bio X Cell).

    Techniques: Flow Cytometry, Enzyme-linked Immunosorbent Assay